Anatomy of female reproductive system

Reading Document

Medical Text Search

female reproductive system anatomy organs structure

Medical Image Search

female reproductive system anatomy diagram

GradeResponse

Anatomy of the Female Reproductive System

The female reproductive system comprises both internal and external organs located primarily in the pelvis. The Müllerian ducts (embryologically) give rise to the uterus, fallopian tubes, cervix, and upper vagina, while the urogenital sinus forms the lower two-thirds of the vagina (Bailey & Love's Surgery, 28th Ed., p. 1596).

Internal Organs

1. Ovaries

Paired, almond-shaped gonads (~3 × 2 × 1 cm)
Located on the lateral pelvic wall, one on each side
Functions: Produce oocytes (eggs) and secrete sex hormones (estrogen, progesterone)
Consist of an outer cortex (contains follicles) and inner medulla (vasculature/stroma)
Blood supply: Ovarian arteries (from abdominal aorta) and branches of uterine arteries

2. Fallopian Tubes (Uterine Tubes)

~10–12 cm long; connect ovaries to the uterus

Four parts (lateral to medial):

Part	Feature
Infundibulum	Funnel-shaped; ends in fimbriae that sweep the oocyte
Ampulla	Widest, longest segment; site of fertilization
Isthmus	Narrow segment near uterus
Intramural (interstitial)	Passes through uterine wall

Lined by ciliated columnar epithelium that propels the ovum toward the uterus

3. Uterus

Hollow, muscular, pear-shaped organ; ~7.5 cm long in nulliparous women
Parts:
- Fundus – dome-shaped top above the fallopian tube openings
- Body (corpus) – main bulk of the uterus
- Isthmus – narrow junction between body and cervix
- Cervix – lower cylindrical portion opening into the vagina
Layers of the uterine wall:
Layer Description
Endometrium Innermost mucosa; cyclically shed during menstruation
Myometrium Thick smooth muscle; contracts during labor
Perimetrium Outer serosal layer (peritoneum)
Normal position: Anteverted and anteflexed
Blood supply: Uterine arteries (from internal iliac arteries)

Layer	Description
Endometrium	Innermost mucosa; cyclically shed during menstruation
Myometrium	Thick smooth muscle; contracts during labor
Perimetrium	Outer serosal layer (peritoneum)

4. Cervix

Lower cylindrical segment of uterus, ~2.5–3 cm long
External os – opening into the vagina
Internal os – opening into the uterine cavity
Cervical canal – connects internal and external os; lined by mucus-secreting columnar epithelium
The transformation zone (squamocolumnar junction) is clinically important — site of cervical dysplasia and carcinoma

5. Vagina

Fibromuscular canal, ~8–10 cm long
Extends from the cervix to the external genitalia
Upper end surrounds the cervix forming vaginal fornices (anterior, posterior, and two lateral)
- The posterior fornix is deepest and relates to the pouch of Douglas (rectouterine pouch)
Lower end opens at the vulva (covered by the hymen in virgins)
Wall layers: Mucosa (non-keratinized stratified squamous epithelium), muscularis, adventitia

External Genitalia (Vulva)

Structure	Description
Mons pubis	Fatty eminence overlying pubic symphysis; covered by pubic hair
Labia majora	Two prominent skin folds; homologous to male scrotum
Labia minora	Inner, hairless folds; enclose the vestibule
Clitoris	Erectile organ at the anterior junction of labia minora; homologous to the penis
Vestibule	Space between the labia minora; contains urethral and vaginal openings
Bartholin's glands	Paired mucus-secreting glands at the posterior vestibule; homologous to Cowper's glands
Hymen	Thin membrane partially covering the vaginal opening

Supporting Ligaments

Ligament	Attachment	Function
Broad ligament	Uterus to lateral pelvic walls (peritoneal fold)	Contains uterine tubes, ovaries, blood vessels
Round ligament	Uterine fundus to labia majora	Maintains anteverted position
Uterosacral ligament	Cervix to sacrum	Primary support; prevents uterine prolapse
Cardinal (Mackenrodt's) ligament	Cervix/vagina to lateral pelvic wall	Main structural support of the uterus
Ovarian ligament	Ovary to uterine wall	Anchors ovary

Blood Supply Summary

Structure	Arterial Supply
Ovaries	Ovarian arteries (aorta)
Uterus & tubes	Uterine arteries (internal iliac)
Vagina (upper)	Uterine + vaginal arteries
Vagina (lower)	Internal pudendal artery
Vulva	Internal & external pudendal arteries

Lymphatic Drainage (Clinically Important)

Structure	Drains to
Ovaries	Para-aortic (lumbar) nodes
Uterine body (upper)	Para-aortic nodes
Uterine body (lower) & cervix	Internal iliac, external iliac, obturator nodes
Vagina (upper)	Internal & external iliac nodes
Vagina (lower) / vulva	Superficial inguinal nodes

Nerve Supply

Sympathetic: T10–L2 (via hypogastric plexus)
Parasympathetic: S2–S4 (pelvic splanchnic nerves)
Somatic (vulva/perineum): Pudendal nerve (S2–S4)

This anatomical framework underpins understanding of menstruation, fertilization, pregnancy, and gynecological pathologies such as endometriosis, fibroids, and ovarian cysts.

Chronic hypertension in pregnancy

Medical Text Search

chronic hypertension in pregnancy definition classification management

Medical Text Search

chronic hypertension pregnancy complications superimposed preeclampsia fetal outcomes

Medical Image Search

hypertension in pregnancy classification management

GradeResponse

Medical Text Search

antihypertensive drugs safe in pregnancy labetalol nifedipine methyldopa

Medical Text Search

chronic hypertension pregnancy monitoring antenatal care delivery timing

Chronic Hypertension in Pregnancy

Definition & Classification

Chronic hypertension in pregnancy is defined as hypertension diagnosed prior to pregnancy or before 20 weeks' gestation. It is distinguished from gestational hypertension and preeclampsia, which arise at ≥20 weeks.

Classification of Hypertensive Disorders of Pregnancy

(ACC/AHA High Blood Pressure Guidelines, p. 65)

Condition	Definition
Chronic hypertension	Diagnosed before pregnancy or at <20 weeks' gestation
Gestational hypertension	De novo hypertension at ≥20 weeks; no proteinuria or end-organ dysfunction
Preeclampsia	Gestational hypertension + proteinuria or end-organ dysfunction
Superimposed preeclampsia	Preeclampsia in a woman with pre-existing chronic hypertension

Severity Classification

Category	Systolic (mmHg)	Diastolic (mmHg)
Mild/non-severe	140–159	90–109
Severe	≥160	≥110

Maternal & Fetal Risks

Chronic hypertension significantly increases risk for both mother and fetus (Harrison's, 21st Ed., p. 13634):

Maternal Risks:

Superimposed preeclampsia — occurs in 20–50% of women with chronic hypertension (ACC/AHA Guidelines, p. 67)
HELLP syndrome (hemolysis, elevated liver enzymes, low platelets)
Eclampsia
Placental abruption
Stroke / hypertensive crisis
Acute kidney injury
Pulmonary edema

Fetal/Neonatal Risks:

Intrauterine growth restriction (IUGR)
Preterm birth
Placental insufficiency
Stillbirth
Neonatal intensive care admission

Superimposed Preeclampsia

This is the most serious complication of chronic hypertension in pregnancy. It is suspected when:

A sudden increase in baseline blood pressure occurs
New-onset or worsening proteinuria develops
New end-organ dysfunction appears (thrombocytopenia, elevated liver enzymes, renal impairment, neurological symptoms, pulmonary edema)

Preconception & Early Pregnancy Assessment

Women with chronic hypertension should undergo a thorough evaluation (Harrison's, p. 13634):

Identify remediable/secondary causes (renal artery stenosis, primary aldosteronism, pheochromocytoma, etc.)
Assess end-organ damage: renal function, proteinuria (baseline), echocardiogram (LVH), ophthalmology (hypertensive retinopathy)
Transition off teratogenic antihypertensives — particularly ACE inhibitors and ARBs (contraindicated; associated with fetal renal dysgenesis and oligohydramnios)

Antihypertensive Treatment in Pregnancy

Target blood pressure: 130–150 mmHg systolic / 80–100 mmHg diastolic — to balance maternal cardiovascular safety with adequate uteroplacental perfusion (Harrison's, p. 13634).

First-Line Agents

Drug	Mechanism	Notes
Labetalol (oral)	α + β blocker	Most commonly used; well-studied safety profile
Nifedipine XL	Calcium channel blocker	Extended-release; effective and well-tolerated
Methyldopa	Central α2-agonist	Long safety record; less preferred due to side effects (sedation)

For Acute/Severe Hypertension (≥160/110 mmHg)

Severe hypertension in pregnancy is an obstetric emergency requiring treatment within 30–60 minutes:

Drug	Route	Dose
Labetalol IV	IV bolus	20 mg IV, repeat 40–80 mg q10–30 min; max 300 mg
Hydralazine IV	IV bolus	5–10 mg IV q20 min
Nifedipine (immediate-release)	Oral	10 mg PO, repeat in 30 min
Nicardipine IV	IV infusion	Used in ICU settings

Contraindicated Drugs

Drug	Reason
ACE inhibitors (e.g., enalapril)	Fetal renal tubular dysplasia, oligohydramnios, skull hypoplasia (2nd/3rd trimester)
ARBs (e.g., losartan)	Same as ACEi
Direct renin inhibitors (aliskiren)	Same as ACEi/ARBs
Atenolol	IUGR, neonatal bradycardia

Aspirin Prophylaxis

Low-dose aspirin (81 mg/day) started at 12–16 weeks is the only routinely recommended intervention to reduce the risk of superimposed preeclampsia in high-risk women (ACC/AHA Guidelines, p. 67).

Antenatal Monitoring

Frequency	Assessment
Every 2–4 weeks (early)	BP monitoring, symptoms
Each visit	Urine protein (dipstick or PCR)
28–32 weeks	Fetal growth ultrasound (for IUGR)
32–36 weeks	Umbilical artery Doppler if growth restriction suspected
32–37 weeks	Fetal surveillance (non-stress test / biophysical profile)

Timing of Delivery

Clinical Scenario	Recommended Delivery Timing
Well-controlled, no complications	38–39 weeks
Difficult to control, end-organ damage	37 weeks
Superimposed preeclampsia without severe features	37 weeks
Superimposed preeclampsia with severe features	34–37 weeks (individualized)
IUGR or deteriorating fetal status	Earlier delivery based on clinical status

Postpartum Considerations

BP often rises in the first 3–5 days postpartum — close monitoring is essential
Antihypertensives should be continued postpartum; most are compatible with breastfeeding (labetalol, nifedipine, enalapril are considered safe for lactation)
ACE inhibitors/ARBs can be restarted postpartum if not breastfeeding, or enalapril/captopril if breastfeeding (low milk transfer)
Screen for underlying secondary hypertension if BP does not normalize by 12 weeks postpartum

Key Takeaways

Chronic hypertension complicates ~1–5% of pregnancies and carries significant maternal and fetal risks
The most feared complication is superimposed preeclampsia (20–50% risk)
Labetalol and extended-release nifedipine are first-line oral agents; target BP 130–150/80–100 mmHg
ACE inhibitors and ARBs are contraindicated throughout pregnancy
Low-dose aspirin from 12–16 weeks reduces superimposed preeclampsia risk
Severe hypertension (≥160/110) requires urgent IV treatment within 30–60 minutes

Cause of preeclampsia

Medical Text Search

preeclampsia etiology pathophysiology causes risk factors

Medical Image Search

preeclampsia pathophysiology placental dysfunction diagram

GradeResponse

Causes & Pathophysiology of Preeclampsia

The precise cause of preeclampsia remains incompletely understood, but current evidence points to a two-stage model rooted in abnormal placentation and subsequent systemic maternal endothelial dysfunction (Harrison's, 21st Ed., p. 13632).

The Two-Stage Model

Stage 1 — Abnormal Placentation (Preclinical) Stage 2 — Systemic Maternal Syndrome (Clinical)

Stage 1: Abnormal Placentation

Under normal conditions, extravillous trophoblast cells invade the maternal spiral arteries and remodel them into wide, low-resistance vessels — ensuring adequate uteroplacental blood flow.

In preeclampsia, this trophoblastic invasion fails, resulting in:

Shallow trophoblast invasion of spiral arteries
Spiral arteries remain narrow, high-resistance, and reactive
Chronic uteroplacental ischemia and ischemia-reperfusion injury
Excessive oxidative stress and reactive oxygen species (ROS) generation

Stage 2: Systemic Maternal Endothelial Dysfunction

The ischemic placenta releases vasoactive and antiangiogenic factors into the maternal circulation, triggering widespread endothelial damage (Harrison's, p. 13632):

Angiogenic Imbalance — Key Mechanism

Factor	Role in Preeclampsia
sFlt-1 (soluble FMS-like tyrosine kinase-1)	Anti-angiogenic; binds and neutralizes free VEGF and PlGF → endothelial dysfunction
Soluble endoglin (sEng)	Antagonizes TGF-β signaling → impairs vasodilation
VEGF (vascular endothelial growth factor)	Normally promotes endothelial health; decreased in preeclampsia
PlGF (placental growth factor)	Angiogenic; markedly reduced → used as a biomarker
TGF-β (transforming growth factor-β)	Vasodilatory; blocked by excess sEng

Excessive placental production of sFlt-1 and sEng creates an anti-angiogenic state, causing systemic endothelial injury (Harrison's, p. 13632).

Pathophysiology Cascade

Preeclampsia Pathophysiology — Prothrombotic State

The diagram above illustrates the downstream consequences of placental ischemia:

Placental ischemia-reperfusion injury → oxidative stress (ROS generation via eNOS uncoupling, NADPH oxidase, xanthine oxidase)
Vascular endothelial dysfunction → upregulation of tissue factor (TF), ICAM, P-selectin
Large VWF multimer formation → platelet activation
Nitric oxide (NO) scavenging → loss of vasodilation → hypertension
Coagulation cascade activation → hypercoagulable, prothrombotic state
End-organ damage → renal dysfunction, cardiac failure, fetal growth restriction (FGR)

Neurological Manifestations

Abnormalities of cerebral circulatory autoregulation underlie the neurological features of preeclampsia (headache, visual disturbances, eclamptic seizures). These autoregulatory failures can cause stroke even at modestly elevated blood pressures (Harrison's, p. 13632).

Contributing Mechanisms Summary

Mechanism	Description
Uteroplacental ischemia	Failed spiral artery remodeling → reduced perfusion
Exaggerated maternal inflammatory response	Systemic activation of innate immunity
Angiogenic imbalance	Excess sFlt-1/sEng; reduced VEGF/PlGF
Endothelial dysfunction	Widespread vascular injury, increased permeability
Oxidative stress	ROS generation → lipid peroxidation, NO depletion
Prothrombotic state	Platelet activation, coagulation cascade → HELLP, thrombosis
Immune maladaptation	Inadequate tolerance to paternal (fetal) antigens

Risk Factors (Predisposing Causes)

Category	Risk Factors
Obstetric	Nulliparity, multiple gestation, molar pregnancy, previous preeclampsia
Medical	Chronic hypertension, pre-existing diabetes, renal disease, autoimmune conditions (SLE, antiphospholipid syndrome)
Maternal	Obesity (BMI >30), age >35, Black race (higher risk & severity)
Genetic	Family history of preeclampsia
Paternal	New partner (reduced immune tolerance), long inter-pregnancy interval
Placental	Thrombophilias, placenta previa, hydrops fetalis

Immune Maladaptation Theory

A widely supported hypothesis is that preeclampsia represents a failure of maternal immune tolerance to paternal/fetal antigens expressed by the placenta. Evidence includes:

Higher risk in first pregnancies (nulliparity)
Protection in subsequent pregnancies with the same partner
Increased risk with donor egg IVF (entirely foreign paternal and maternal antigens)
Reduced risk with longer sexual cohabitation before pregnancy (immune tolerance builds over time)

Why Delivery Cures Preeclampsia

The placenta is the source of the pathological process. Delivery of the placenta removes the trigger, which is why delivery remains the only definitive treatment — explaining why preterm delivery is often necessary in severe cases.

Key Takeaway

Preeclampsia is fundamentally a placental disease that manifests as a maternal systemic syndrome. The core sequence is:

Failed trophoblast invasion → uteroplacental ischemia → oxidative stress → angiogenic imbalance (↑sFlt-1, ↓VEGF/PlGF) → endothelial dysfunction → hypertension + proteinuria + end-organ damage

Hypertension disease in pregnancy

Medical Text Search

hypertensive disorders of pregnancy classification diagnosis criteria

Medical Image Search

hypertensive disorders pregnancy preeclampsia eclampsia HELLP

GradeResponse

Medical Text Search

preeclampsia eclampsia HELLP syndrome diagnosis management treatment

Medical Text Search

gestational hypertension management antihypertensive delivery timing pregnancy

GradeResponse

Hypertensive Disorders of Pregnancy (HDP)

Hypertensive disorders complicate 5–10% of all pregnancies and are a leading cause of maternal and perinatal morbidity and mortality worldwide.

Classification

(ACC/AHA BP Guidelines, p. 65)

Condition	Definition
Chronic Hypertension	Pre-existing diagnosis OR BP ≥140/90 mmHg on 2 occasions ≥4 hours apart before 20 weeks' gestation
Gestational Hypertension	De novo hypertension at ≥20 weeks; no proteinuria or end-organ dysfunction
Preeclampsia	Gestational hypertension + proteinuria or end-organ dysfunction
Superimposed Preeclampsia	Preeclampsia developing in a woman with pre-existing chronic hypertension
Eclampsia	New-onset generalized tonic-clonic seizures in a patient with preeclampsia

(ACOG/ACC/AHA criteria — ACC/AHA Guidelines, p. 64–65)

1. Chronic Hypertension in Pregnancy

Defined as BP ≥140/90 mmHg before 20 weeks or pre-existing
Carries risk of superimposed preeclampsia (20–50%), IUGR, placental abruption
Treatment: Labetalol, extended-release nifedipine, or methyldopa
Target BP: 130–150 / 80–100 mmHg
Contraindicated: ACE inhibitors, ARBs (fetal renal toxicity)
Low-dose aspirin 81 mg/day from 12–16 weeks to reduce preeclampsia risk

2. Gestational Hypertension

De novo BP ≥140/90 mmHg at ≥20 weeks without proteinuria or end-organ dysfunction
Resolves within 12 weeks postpartum (if persistent → reclassified as chronic hypertension)
~25–50% progress to preeclampsia — requires close monitoring
Management:
- Mild (140–159/90–109): Outpatient monitoring; antihypertensives if BP sustained
- Severe (≥160/110): Hospitalize; treat urgently; deliver at 37 weeks
- Fetal surveillance and growth scans from 32 weeks

3. Preeclampsia

A multiorgan inflammatory syndrome characterized by hypertension plus proteinuria or end-organ dysfunction (ACC/AHA Guidelines, p. 67).

Diagnostic Criteria (ACOG)

Hypertension: BP ≥140/90 mmHg on 2 occasions ≥4 hours apart at ≥20 weeks

Plus at least one of:

Criterion	Threshold
Proteinuria	≥300 mg/24h OR protein:creatinine ratio ≥0.3 OR dipstick ≥2+
Thrombocytopenia	Platelets <100,000/μL
Renal insufficiency	Creatinine >1.1 mg/dL or doubling of baseline
Impaired liver function	LFTs >2× upper limit; severe RUQ/epigastric pain
Pulmonary edema	New onset
Neurological symptoms	New-onset headache unresponsive to analgesia, visual disturbances

Severe Features

Feature	Criterion
Severe hypertension	BP ≥160/110 mmHg on 2 occasions ≥4 hours apart
Thrombocytopenia	Platelets <100,000/μL
Renal impairment	Creatinine >1.1 mg/dL
Hepatic dysfunction	Transaminases ≥2× normal; severe RUQ pain
Pulmonary edema	—
New-onset headache/visual disturbances	Unresponsive to medication

Pathophysiology (Brief)

Failed trophoblast invasion → uteroplacental ischemia → oxidative stress → excess sFlt-1/sEng → endothelial dysfunction → hypertension + proteinuria + end-organ damage

Management of Preeclampsia

Aspect	Detail
Definitive treatment	Delivery (only cure)
Seizure prophylaxis	Magnesium sulfate IV (loading 4–6 g, then 1–2 g/hr infusion)
Antihypertensives	IV labetalol, IV hydralazine, oral nifedipine (for acute severe HTN)
Corticosteroids	Betamethasone/dexamethasone if <34 weeks (fetal lung maturity)
Aspirin prophylaxis	81 mg/day from 12–16 weeks (high-risk women)

Delivery Timing

Scenario	Timing
Preeclampsia without severe features	37 weeks
Preeclampsia with severe features	34 weeks (after steroids)
Uncontrolled severe HTN, deteriorating status	Immediate delivery

4. HELLP Syndrome

A severe variant of preeclampsia:

Letter	Finding	Diagnostic Threshold
H	Hemolysis	Microangiopathic hemolytic anemia on smear; elevated LDH, low haptoglobin
EL	Elevated Liver enzymes	AST/ALT >70 IU/L
LP	Low Platelets	<100,000/μL

May present without hypertension or proteinuria in ~15–20%
Presents with: epigastric/RUQ pain, nausea/vomiting, malaise
Management: Stabilize, magnesium sulfate, urgent delivery (≥34 weeks); transfuse if platelets <50,000 before cesarean
Complications: DIC, liver hematoma/rupture, acute renal failure, pulmonary edema

5. Eclampsia

Definition: New-onset generalized tonic-clonic seizures in a preeclamptic patient — the most severe neurological complication
Can occur antepartum (>50%), intrapartum, or postpartum (up to 48 hrs after delivery)
1 in 200 preeclampsia cases progress to eclampsia without treatment (Harrison's, p. 13632)

Management of Eclamptic Seizure

Airway, Breathing, Circulation (ABC) — lateral decubitus position, oxygen
Magnesium sulfate — 4–6 g IV over 15–20 min (first-line anticonvulsant and prophylaxis)
Control BP — IV labetalol or hydralazine if ≥160/110 mmHg
Deliver after stabilization — mode based on obstetric factors
Continue MgSO₄ for 24 hours postpartum

Note: Diazepam/phenytoin are second-line only; magnesium sulfate is superior for eclampsia prevention and treatment.

6. Superimposed Preeclampsia

Occurs in 20–50% of women with chronic hypertension (ACC/AHA Guidelines, p. 67)
Diagnosed when a woman with chronic hypertension develops:
- Sudden worsening of BP
- New or worsening proteinuria
- New end-organ dysfunction (thrombocytopenia, elevated LFTs, renal impairment, pulmonary edema, neurological symptoms)
Carries the highest risk of all HDPs for maternal and fetal complications

Maternal & Fetal Complications Overview

Complication	Condition
Stroke	Severe preeclampsia, eclampsia
Pulmonary edema	Preeclampsia with severe features, HELLP
Acute kidney injury	Preeclampsia, HELLP
DIC	HELLP, severe preeclampsia
Liver rupture	HELLP
Placental abruption	All HDPs, especially chronic HTN
Preterm birth	All HDPs
IUGR / stillbirth	Chronic HTN, preeclampsia
Neonatal ICU admission	Preterm delivery in all HDPs

Prevention Summary

Intervention	Indication
Low-dose aspirin 81 mg/day (from 12–16 weeks)	High-risk women (chronic HTN, prior preeclampsia, multifetal pregnancy, diabetes, renal disease, autoimmune disease)
Calcium supplementation (1.5–2 g/day)	Women with low dietary calcium intake
Weight optimization preconception	Obesity is a major modifiable risk factor
Antihypertensive optimization preconception	Stop ACEi/ARBs; switch to safe agents

Key Points

HDPs are classified into 4 main types: chronic hypertension, gestational hypertension, preeclampsia, and superimposed preeclampsia
Magnesium sulfate + antihypertensives are the mainstay of preeclampsia/eclampsia treatment (ACC/AHA Guidelines, p. 67)
Delivery is the only cure — timing is individualized based on severity and gestational age
Postpartum surveillance is essential — HDPs (especially eclampsia) can occur up to 6 weeks postpartum

This is a shared conversation. Sign in to Orris to start your own chat.